Enhancing the Effect of Nerve Blocks in upper limb Surgery with Dexmedetomidine

Effect of adding dexmedetomidine to lignocaine with adrenaline in supraclavicular brachial plexus block for approval of subject

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/093726

Enrollment

Registered

2025-08-27

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: dexmedetomidine: Patients will receive 7 milligram per kilogram body weight 1.5 percentage lignocaine adrenaline with 50 microgram (0.5 ml) dexmedetomidine in supraclavicular brachial

Eligibility

Inclusion criteria

Inclusion criteria: 1)ASA1 and ASA2,2)Age group between 18 to 60 years,3)Patient giving consent for study

Exclusion criteria

Exclusion criteria: severe respiratory and cardiovascular disease patients,sensitivity to study drug,known history of bleeding tendency or deranged coagulogram,duration of surgery more than 2 hours,patients with neurodeficit involving brachial plexus,pregnant patients,patients on any alpha2 agonist or antagonist tratment,drug abusers and psychiatric patients

Design outcomes

Primary

Measure	Time frame
to determine the duration of analgesiaTimepoint: 12 hours	—

Secondary

Measure	Time frame
To determine the onset and duration of sensory and motor block,To determine the effect on haemodynamic parameters,To observe side effects, if any. Timepoint: 12 hours	—

Countries

India

Contacts

Public ContactDr Sabhayata sharma

Government multispeciality hospital

kaurvineet1973@gmail.com9876797338

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026